trial summary · NCT07700927
Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection
Acute Management of PJI With Local Implant Retention and Antibiotics Using the Sola2 AMF Knee System: A Multicenter Double-blind Clinical Trial.
Trial record from the TrialBase DB dataset, status RECRUITING, condition Prosthetic Joint Infection of Knee, sponsored by Solenic Medical, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection. The main questions this study aims to answer are: 1. Whether adding the Sola2 AMF Knee System improves knee function and quality of life at 6 months. 2. Whether adding the Sola2 AMF Knee System to surgery and antibiotic treatment affects the need for additional infection-related surgery. 3. Whether the Sola2 AMF Knee System can be used safely, based on device-related adverse events through 12 months. This study has two stages. In Stage 1, participants will be enrolled into sequential sentinel groups at increasing AMF temperature levels. All sentinel participants will receive active Sola2 AMF treatment. A safety review will occur after each sentinel group before proceeding to the next group. In Stage 2, researchers will compare participants who receive active Sola2 AMF treatment to participants who receive sham AMF treatment. All participants will receive surgery called debridement, antibiotics, and implant retention (DAIR), and antibiotic treatment for knee implant infection. Participants will: * Have DAIR surgery for knee implant infection; * Receive pathogen-appropriate antibiotic treatment from the study doctor; * If enrolled in Stage 1, receive active Sola2 AMF treatment at the designated sentinel temperature level; * If enrolled in Stage 2, receive either active Sola2 AMF treatment or sham AMF treatment, depending on randomization assignment …
Source record: https://clinicaltrials.gov/study/NCT07700927
Facts
| registry id | NCT07700927 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Prosthetic Joint Infection of Knee |
| sponsor | Solenic Medical, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 165 |
| start date | 2026-10-30 |
| primary completion | 2028-08 |
| completion | 2029-08 |
| results posted | not reported |
Conditions
- Prosthetic Joint Infection of Knee
Interventions
- Intervention 1: Alternating Magnetic Field Treatment
- Intervention 2 - Sham Treatment
- Debridement, Antibiotics, Implant Retention
Countries
- United States
Intervention types: DEVICE, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.